Manipulation of BCG vaccine: a double-edged sword

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 35, Issue 4, 2016, Pages 535-543

  Singh, V K ^a   Srivastava, R ^b   Srivastava, B S ^b  

^a LUND UNIVERSITY   (Sweden)

^b CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; RECOMBINANT VACCINE; BACTERIAL ANTIGEN;

BCG VACCINATION; HETEROLOGOUS EXPRESSION; HUMAN; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; MYCOBACTERIUM BOVIS; PATHOGENICITY; PROCEDURES; VIRULENCE;

ANTIGENS, BACTERIAL; BCG VACCINE; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM BOVIS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VACCINES, SYNTHETIC; VIRULENCE;

EID: 84955279310     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-016-2579-y     Document Type: Review

References (103)

1. Bloom BR, Murray CJ (1992) Tuberculosis: commentary on a reemergent killer. Science 57:1055–1064
2. Sakula A (1983) BCG: who were Calmette and Guérin? Thorax 38:806–812
3. Brosch R, Gordon SV, Pym A, Eiglmeier K, Garnier T, Cole ST (2000) Comparative genomics of the mycobacteria. Int J Med Microbiol 290:143–152. doi:10.1016/S1438-4221(00)80083-1
4. Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D et al (1998) Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393:537–544. doi:10.1038/31159
5. Joung SM, Ryoo S (2013) BCG vaccine in Korea. Clin Exp Vaccine Res 2:83–91. doi:10.7774/cevr.2013.2.2.83
6. Behr MA, Wilson MA, Gill WP, Salamon H, Schoolnik GK, Rane S et al (1999) Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284:1520–1523
7. Tripathy SP (1983) The case for B.C.G. Ann Natl Acad Med Sci 19:11–21
8. da Costa AC, Nogueira SV, Kipnis A, Junqueira-Kipnis AP (2014) Recombinant BCG: innovations on an Old vaccine. Scope of BCG strains and strategies to improve long-lasting memory. Front Immunol 5:152. doi:10.3389/fimmu.2014.00152
9. Cooper AM (2009) Cell-mediated immune responses in tuberculosis. Annu Rev Immunol 27:393–422. doi:10.1146/annurev.immunol.021908.132703
10. Pearl JE, Torrado E, Tighe M, Fountain JJ, Solache A, Strutt T et al (2012) Nitric oxide inhibits the accumulation of CD4+CD44hiTbet+CD69lo T cells in mycobacterial infection. Eur J Immunol 42:3267–3279. doi:10.1002/eji.201142158
11. Geldmacher C, Zumla A, Hoelscher M (2012) Interaction between HIV and Mycobacterium tuberculosis: HIV-1-induced CD4 T-cell depletion and the development of active tuberculosis. Curr Opin HIV AIDS 7:268–275. doi:10.1097/COH.0b013e3283524e32
12. O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MPR (2013) The immune response in tuberculosis. Annu Rev Immunol 31:475–527. doi:10.1146/annurev-immunol-032712-095939
13. Robinson RT, Orme IM, Cooper AM (2015) The onset of adaptive immunity in the mouse model of tuberculosis and the factors that compromise its expression. Immunol Rev 264:46–59. doi:10.1111/imr.12259
14. Schlesinger LS (1996) Entry of Mycobacterium tuberculosis into mononuclear phagocytes. Curr Top Microbiol Immunol 215:71–96
15. Eum S-Y, Kong J-H, Hong M-S, Lee Y-J, Kim J-H, Hwang S-H et al (2010) Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary TB. Chest 137:122–128. doi:10.1378/chest.09-0903
16. Wolf AJ, Linas B, Trevejo-Nuñez GJ, Kincaid E, Tamura T, Takatsu K et al (2007) Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo. J Immunol 179:2509–2519
17. Bhatt K, Salgame P (2007) Host innate immune response to Mycobacterium tuberculosis. J Clin Immunol 27:347–362. doi:10.1007/s10875-007-9084-0
18. Chen M, Gan H, Remold HG (2006) A mechanism of virulence: virulent Mycobacterium tuberculosis strain H37Rv, but not attenuated H37Ra, causes significant mitochondrial inner membrane disruption in macrophages leading to necrosis. J Immunol 176:3707–3716
19. Flynn JL, Chan J (2001) Immunology of tuberculosis. Annu Rev Immunol 19:93–129. doi:10.1146/annurev.immunol.19.1.93
20. Chen M, Divangahi M, Gan H, Shin DSJ, Hong S, Lee DM et al (2008) Lipid mediators in innate immunity against tuberculosis: opposing roles of PGE2 and LXA4 in the induction of macrophage death. J Exp Med 205:2791–2801. doi:10.1084/jem.20080767
21. Divangahi M, Chen M, Gan H, Desjardins D, Hickman TT, Lee DM et al (2009) Mycobacterium tuberculosis evades macrophage defenses by inhibiting plasma membrane repair. Nat Immunol 10:899–906. doi:10.1038/ni.1758
22. Behar SM, Divangahi M, Remold HG (2010) Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nat Rev Microbiol 8:668–674. doi:10.1038/nrmicro2387
23. Elkington P, Shiomi T, Breen R, Nuttall RK, Ugarte-Gil CA, Walker NF et al (2011) MMP-1 drives immunopathology in human tuberculosis and transgenic mice. J Clin Invest 121:1827–1833. doi:10.1172/JCI45666
24. Elkington PTG, Nuttall RK, Boyle JJ, O’Kane CM, Horncastle DE, Edwards DR et al (2005) Mycobacterium tuberculosis, but not vaccine BCG, specifically upregulates matrix metalloproteinase-1. Am J Respir Crit Care Med 172:1596–1604. doi:10.1164/rccm.200505-753OC
25. Elkington PT, Ugarte-Gil CA, Friedland JS (2011) Matrix metalloproteinases in tuberculosis. Eur Respir J 38:456–464. doi:10.1183/09031936.00015411
26. Flynn JL, Goldstein MM, Chan J, Triebold KJ, Pfeffer K, Lowenstein CJ et al (1995) Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2:561–572
27. Blomgran R, Ernst JD (2011) Lung neutrophils facilitate activation of naive antigen-specific CD4+ T cells during Mycobacterium tuberculosis infection. J Immunol 186:7110–7119. doi:10.4049/jimmunol.1100001
28. Majlessi L, Prados-Rosales R, Casadevall A, Brosch R (2015) Release of mycobacterial antigens. Immunol Rev 264:25–45. doi:10.1111/imr.12251
29. Bottai D, Brosch R (2009) Mycobacterial PE, PPE and ESX clusters: novel insights into the secretion of these most unusual protein families. Mol Microbiol 73:325–328. doi:10.1111/j.1365-2958.2009.06784.x
30. Gey van Pittius NC, Sampson SL, Lee H, Kim Y, van Helden PD, Warren RM (2006) Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions. BMC Evol Biol 6:95. doi:10.1186/1471-2148-6-95
31. Daleke MH, Cascioferro A, de Punder K, Ummels R, Abdallah AM, van der Wel N et al (2011) Conserved Pro-Glu (PE) and Pro-Pro-Glu (PPE) protein domains target LipY lipases of pathogenic mycobacteria to the cell surface via the ESX-5 pathway. J Biol Chem 286:19024–19034. doi:10.1074/jbc.M110.204966
32. [No authors listed] (1999) Fifteen year follow up of trial of BCG vaccines in south India for tuberculosis prevention. Tuberculosis research centre (ICMR), Chennai. Indian J Med Res 110:56–69
33. Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV et al (1994) Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698–702
34. Black GF, Dockrell HM, Crampin AC, Floyd S, Weir RE, Bliss L et al (2001) Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi. J Infect Dis 184:322–329. doi:10.1086/322042
35. Fine PE (1995) Variation in protection by BCG: implications of and for heterologous immunity. Lancet 346:1339–1345
36. Bastos RG, Borsuk S, Seixas FK, Dellagostin OA (2009) Recombinant Mycobacterium bovis BCG. Vaccine 27:6495–6503. doi:10.1016/j.vaccine.2009.08.044
37. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galic’ S (2000) Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. Proc Natl Acad Sci U S A 97:13853–13858. doi:10.1073/pnas.250480397
38. Wangoo A, Brown IN, Marshall BG, Cook HT, Young DB, Shaw RJ (2000) Bacille Calmette-Guérin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-gamma). Clin Exp Immunol 119:92–98
39. Murray PJ, Aldovini A, Young RA (1996) Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines. Proc Natl Acad Sci U S A 93:934–939
40. Singh VK, Srivastava V, Singh V, Rastogi N, Roy R, Shaw AK et al (2011) Overexpression of Rv3097c in Mycobacterium bovis BCG abolished the efficacy of BCG vaccine to protect against Mycobacterium tuberculosis infection in mice. Vaccine 29:4754–4760. doi:10.1016/j.vaccine.2011.04.086
41. Behr MA (2002) BCG—different strains, different vaccines? Lancet Infect Dis 2:86–92
42. Behr MA, Small PM (1997) Has BCG attenuated to impotence? Nature 389:133–134. doi:10.1038/38151
43. Gordon SV, Brosch R, Billault A, Garnier T, Eiglmeier K, Cole ST (1999) Identification of variable regions in the genomes of tubercle bacilli using bacterial artificial chromosome arrays. Mol Microbiol 32:643–655
44. Jungblut PR, Schaible UE, Mollenkopf HJ, Zimny-Arndt U, Raupach B, Mattow J et al (1999) Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens. Mol Microbiol 33:1103–1117
45. Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK (1996) Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol 178:1274–1282
46. Pym AS, Brodin P, Majlessi L, Brosch R, Demangel C, Williams A et al (2003) Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med 9:533–539. doi:10.1038/nm859
47. Kaufmann SHE, Baumann S, Nasser Eddine A (2006) Exploiting immunology and molecular genetics for rational vaccine design against tuberculosis. Int J Tuberc Lung Dis 10:1068–1079
48. Weinrich Olsen A, van Pinxteren LA, Meng Okkels L, Birk Rasmussen P, Andersen P (2001) Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85b and esat-6. Infect Immun 69:2773–2778. doi:10.1128/IAI.69.5.2773-2778.2001
49. Goonetilleke NP, McShane H, Hannan CM, Anderson RJ, Brookes RH, Hill AVS (2003) Enhanced immunogenicity and protective efficacy against Mycobacterium tuberculosis of bacille Calmette-Guérin vaccine using mucosal administration and boosting with a recombinant modified vaccinia virus Ankara. J Immunol 171:1602–1609
50. Agger EM, Andersen P (2002) A novel TB vaccine; towards a strategy based on our understanding of BCG failure. Vaccine 21:7–14
51. Grode L, Seiler P, Baumann S, Hess J, Brinkmann V, Nasser Eddine A et al (2005) Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin. J Clin Invest 115:2472–2479. doi:10.1172/JCI24617
52. Desel C, Dorhoi A, Bandermann S, Grode L, Eisele B, Kaufmann SHE (2011) Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 204:1573–1584. doi:10.1093/infdis/jir592
53. Stenger S, Mazzaccaro RJ, Uyemura K, Cho S, Barnes PF, Rosat JP et al (1997) Differential effects of cytolytic T cell subsets on intracellular infection. Science 276:1684–1687
54. Cho S, Mehra V, Thoma-Uszynski S, Stenger S, Serbina N, Mazzaccaro RJ et al (2000) Antimicrobial activity of MHC class I-restricted CD8+ T cells in human tuberculosis. Proc Natl Acad Sci U S A 97:12210–12215. doi:10.1073/pnas.210391497
55. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR (1992) Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc Natl Acad Sci U S A 89:12013–12017
56. Britton WJ, Palendira U (2003) Improving vaccines against tuberculosis. Immunol Cell Biol 81:34–45. doi:10.1046/j.0818-9641.2002.01143.x
57. Fine PE (1989) The BCG story: lessons from the past and implications for the future. Rev Infect Dis 11(Suppl 2):S353–S359
58. Palmer CE, Long MW (1966) Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis. Am Rev Respir Dis 94:553–568
59. Rook GA, Bahr GM, Stanford JL (1981) The effect of two distinct forms of cell-mediated response to mycobacteria on the protective efficacy of BCG. Tubercle 62:63–68
60. Hernandez-Pando R, Pavön L, Arriaga K, Orozco H, Madrid-Marina V, Rook G (1997) Pathogenesis of tuberculosis in mice exposed to low and high doses of an environmental mycobacterial saprophyte before infection. Infect Immun 65:3317–3327
61. Seah GT, Scott GM, Rook GA (2000) Type 2 cytokine gene activation and its relationship to extent of disease in patients with tuberculosis. J Infect Dis 181:385–389. doi:10.1086/315200
62. Luo Y, Chen X, Han R, O’Donnell MA (2001) Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity. Clin Exp Immunol 123:264–270
63. Brandt L, Oettinger T, Holm A, Andersen AB, Andersen P (1996) Key epitopes on the ESAT-6 antigen recognized in mice during the recall of protective immunity to Mycobacterium tuberculosis. J Immunol 157:3527–3533
64. Andersen P, Andersen AB, Sørensen AL, Nagai S (1995) Recall of long-lived immunity to Mycobacterium tuberculosis infection in mice. J Immunol 154:3359–3372
65. Lalvani A, Nagvenkar P, Udwadia Z, Pathan AA, Wilkinson KA, Shastri JS et al (2001) Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians. J Infect Dis 183:469–477. doi:10.1086/318081
66. Ravn P, Demissie A, Eguale T, Wondwosson H, Lein D, Amoudy HA et al (1999) Human T cell responses to the ESAT-6 antigen from Mycobacterium tuberculosis. J Infect Dis 179:637–645. doi:10.1086/314640
67. Kamath AT, Feng CG, Macdonald M, Briscoe H, Britton WJ (1999) Differential protective efficacy of DNA vaccines expressing secreted proteins of Mycobacterium tuberculosis. Infect Immun 67:1702–1707
68. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S (1999) Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun 67:4780–4786
69. Brandt L, Elhay M, Rosenkrands I, Lindblad EB, Andersen P (2000) ESAT-6 subunit vaccination against Mycobacterium tuberculosis. Infect Immun 68:791–795
70. Olsen AW, Hansen PR, Holm A, Andersen P (2000) Efficient protection against Mycobacterium tuberculosis by vaccination with a single subdominant epitope from the ESAT-6 antigen. Eur J Immunol 30:1724–1732. doi:10.1002/1521-4141(200006)30:6<1724::AID-IMMU1724>3.0.CO;2-A
71. Alexandroff AB, Jackson AM, O’Donnell MA, James K (1999) BCG immunotherapy of bladder cancer: 20 years on. Lancet 353:1689–1694. doi:10.1016/S0140-6736(98)07422-4
72. O’Donnell MA, Aldovini A, Duda RB, Yang H, Szilvasi A, Young RA et al (1994) Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes. Infect Immun 62:2508–2514
73. Young SL, O’Donnell MA, Buchan GS (2002) IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosuppression to elicit a Type 1 immune response. Int Immunol 14:793–800
74. Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C (2002) Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice. Infect Immun 70:6549–6557
75. Hoft DF, Blazevic A, Abate G, Hanekom WA, Kaplan G, Soler JH et al (2008) A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. J Infect Dis 198:1491–1501. doi:10.1086/592450
76. Dhar N, Rao V, Tyagi AK (2004) Immunogenicity of recombinant BCG vaccine strains overexpressing components of the antigen 85 complex of Mycobacterium tuberculosis. Med Microbiol Immunol 193:19–25. doi:10.1007/s00430-002-0170-x
77. Sugawara I, Li Z, Sun L, Udagawa T, Taniyama T (2007) Recombinant BCG Tokyo (Ag85A) protects cynomolgus monkeys (Macaca fascicularis) infected with H37Rv Mycobacterium tuberculosis. Tuberculosis (Edinb) 87:518–525. doi:10.1016/j.tube.2007.06.002
78. Badell E, Nicolle F, Clark S, Majlessi L, Boudou F, Martino A et al (2009) Protection against tuberculosis induced by oral prime with Mycobacterium bovis BCG and intranasal subunit boost based on the vaccine candidate Ag85B-ESAT-6 does not correlate with circulating IFN-gamma producing T-cells. Vaccine 27:28–37. doi:10.1016/j.vaccine.2008.10.034
79. Qie YQ, Wang JL, Zhu BD, Xu Y, Wang QZ, Chen JZ et al (2008) Evaluation of a new recombinant BCG which contains mycobacterial antigen ag85B-mpt64(190-198)-mtb8.4 in C57/BL6 mice. Scand J Immunol 67:133–139. doi:10.1111/j.1365-3083.2007.02048.x
80. Tang C, Yamada H, Shibata K, Maeda N, Yoshida S, Wajjwalku W et al (2008) Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis. J Infect Dis 197:1263–1274. doi:10.1086/586902
81. Lin C-W, Su I-J, Chang J-R, Chen Y-Y, Lu J-J, Dou H-Y (2012) Recombinant BCG coexpressing Ag85B, CFP10, and interleukin-12 induces multifunctional Th1 and memory T cells in mice. APMIS 120:72–82. doi:10.1111/j.1600-0463.2011.02815.x
82. Chen Y-Y, Lin C-W, Huang W-F, Chang J-R, Su I-J, Hsu C-H et al (2014) Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis. J Microbiol Immunol Infect. doi:10.1016/j.jmii.2014.11.019
83. Ahsan MJ (2015) Recent advances in the development of vaccines for tuberculosis. Ther Adv Vaccines 3:66–75. doi:10.1177/2051013615593891
84. Waters WR, Palmer MV, Buddle BM, Vordermeier HM (2012) Bovine tuberculosis vaccine research: historical perspectives and recent advances. Vaccine 30:2611–2622. doi:10.1016/j.vaccine.2012.02.018
85. Buddle BM, Wedlock DN, Denis M, Vordermeier HM, Hewinson RG (2011) Update on vaccination of cattle and wildlife populations against tuberculosis. Vet Microbiol 151:14–22. doi:10.1016/j.vetmic.2011.02.021
86. Hu X-D, Yu D-H, Chen S-T, Li S-X, Cai H (2009) A combined DNA vaccine provides protective immunity against Mycobacterium bovis and Brucella abortus in cattle. DNA Cell Biol 28:191–199. doi:10.1089/dna.2008.0790
87. Vordermeier HM, Villarreal-Ramos B, Cockle PJ, McAulay M, Rhodes SG, Thacker T et al (2009) Viral booster vaccines improve Mycobacterium bovis BCG-induced protection against bovine tuberculosis. Infect Immun 77:3364–3373. doi:10.1128/IAI.00287-09
88. Wedlock DN, Denis M, Painter GF, Ainge GD, Vordermeier HM, Hewinson RG et al (2008) Enhanced protection against bovine tuberculosis after coadministration of Mycobacterium bovis BCG with a Mycobacterial protein vaccine-adjuvant combination but not after coadministration of adjuvant alone. Clin Vaccine Immunol 15:765–772. doi:10.1128/CVI.00034-08
89. Wedlock DN, Denis M, Skinner MA, Koach J, de Lisle GW, Vordermeier HM et al (2005) Vaccination of cattle with a CpG oligodeoxynucleotide-formulated mycobacterial protein vaccine and Mycobacterium bovis BCG induces levels of protection against bovine tuberculosis superior to those induced by vaccination with BCG alone. Infect Immun 73:3540–3546. doi:10.1128/IAI.73.6.3540-3546.2005
90. Rizzi C, Bianco MV, Blanco FC, Soria M, Gravisaco MJ, Montenegro V et al (2012) Vaccination with a BCG strain overexpressing Ag85B protects cattle against Mycobacterium bovis challenge. PLoS One 7, e51396. doi:10.1371/journal.pone.0051396
91. Horwitz MA, Harth G, Dillon BJ, Maslesa-Galić S (2006) A novel live recombinant mycobacterial vaccine against bovine tuberculosis more potent than BCG. Vaccine 24:1593–1600. doi:10.1016/j.vaccine.2005.10.002
92. Blanco FC, Bianco MV, Garbaccio S, Meikle V, Gravisaco MJ, Montenegro V et al (2013) Mycobacterium bovis Δmce2 double deletion mutant protects cattle against challenge with virulent M. bovis. Tuberculosis (Edinb) 93:363–372. doi:10.1016/j.tube.2013.02.004
93. Khatri B, Whelan A, Clifford D, Petrera A, Sander P, Vordermeier HM (2014) BCG Δzmp1 vaccine induces enhanced antigen specific immune responses in cattle. Vaccine 32:779–784. doi:10.1016/j.vaccine.2013.12.055
94. García E, Bianco MV, Gravisaco MJ, Rocha RV, Blanco FC, Bigi F (2015) Evaluation of Mycobacterium bovis double knockout mce2-phoP as candidate vaccine against bovine tuberculosis. Tuberculosis (Edinb) 95:186–189. doi:10.1016/j.tube.2015.01.001
95. Tompkins DM, Ramsey DSL, Cross ML, Aldwell FE, de Lisle GW, Buddle BM (2009) Oral vaccination reduces the incidence of tuberculosis in free-living brushtail possums. Proc Biol Sci 276:2987–2995. doi:10.1098/rspb.2009.0414
96. Murphy D, Costello E, Aldwell FE, Lesellier S, Chambers MA, Fitzsimons T et al (2014) Oral vaccination of badgers (Meles meles) against tuberculosis: comparison of the protection generated by BCG vaccine strains Pasteur and Danish. Vet J 200:362–367. doi:10.1016/j.tvjl.2014.02.031
97. Yeremeev VV, Stewart GR, Neyrolles O, Skrabal K, Avdienko VG, Apt AS et al (2000) Deletion of the 19kDa antigen does not alter the protective efficacy of BCG. Tuber Lung Dis 80:243–247. doi:10.1054/tuld.2000.0252
98. Rao V, Dhar N, Shakila H, Singh R, Khera A, Jain R et al (2005) Increased expression of Mycobacterium tuberculosis 19 kDa lipoprotein obliterates the protective efficacy of BCG by polarizing host immune responses to the Th2 subtype. Scand J Immunol 61:410–417. doi:10.1111/j.1365-3083.2005.01569.x
99. Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer—a current perspective. Nat Rev Urol 11:153–162. doi:10.1038/nrurol.2014.15
100. Streit JA, Recker TJ, Donelson JE, Wilson ME (2000) BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice. Exp Parasitol 94:33–41. doi:10.1006/expr.1999.4459
101. Varaldo PB, Leite LCC, Dias WO, Miyaji EN, Torres FIG, Gebara VC et al (2004) Recombinant Mycobacterium bovis BCG expressing the Sm14 antigen of Schistosoma mansoni protects mice from cercarial challenge. Infect Immun 72:3336–3343. doi:10.1128/IAI.72.6.3336-3343.2004
102. Seixas FK, da Silva EF, Hartwig DD, Cerqueira GM, Amaral M, Fagundes MQ et al (2007) Recombinant Mycobacterium bovis BCG expressing the LipL32 antigen of Leptospira interrogans protects hamsters from challenge. Vaccine 26:88–95. doi:10.1016/j.vaccine.2007.10.052
103. Govan VA, Christensen ND, Berkower C, Jacobs WR Jr, Williamson A-L (2006) Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 24:2087–2093. doi:10.1016/j.vaccine.2005.11.029